


## Isometronidazole

## Chemical Properties

CAS No. :	705-19-1
Formula:	C <sub>6</sub> H <sub>9</sub> N <sub>3</sub> O <sub>3</sub>
Molecular Weight:	171.16
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	<p>Isometronidazole (RO-07-1502) is a chemical compound. The chemical compound is a derivative of the nitroimidazole family. Its molecular formula is C<sub>6</sub>H<sub>9</sub>N<sub>3</sub>O<sub>3</sub>. Isometronidazole can actually be used in the treatment of radiation therapy. The compound is known as a hypoxic cell sensitizer (radiosensitizer), increasing the efficacy of radiation treatment.</p> <p>Isometronidazole (RO-07-1502), a nitroimidazole derivative with the molecular formula C<sub>6</sub>H<sub>9</sub>N<sub>3</sub>O<sub>3</sub>, acts as a hypoxic cell sensitizer (radiosensitizer) in radiation therapy, enhancing the efficacy of the treatment.</p>
Targets(IC50)	Others

## Solubility Information

Solubility	DMSO: Soluble, (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	5.8425 mL	29.2124 mL	58.4249 mL
5 mM	1.1685 mL	5.8425 mL	11.685 mL
10 mM	0.5842 mL	2.9212 mL	5.8425 mL
50 mM	0.1168 mL	0.5842 mL	1.1685 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

- Schreiber A, Krause M, Zips D, Dörfler A, Richter K, Vettermann S, Petersen C, Beuthien-Baumann B, Thümmeler D, Baumann M. Effect of the hypoxic cell sensitizer isometronidazole on local control of two human squamous cell carcinomas after fractionated irradiation. *Strahlenther Onkol.* 2004 Jun;180(6):375-82. PubMed PMID: 15175873.
- Hentschel M, Schmidt W. Pharmacokinetics of isometronidazole. Basic model and estimation of the kinetic parameters from experimental data. *Pharmazie.* 1992 Mar;47(3):221-4. PubMed PMID: 1615029.
- Kob D, Lilienthal A, Bauhardt H, Merkle K, Schröder E, Schröder E, Hentschel M. [The radiation-sensitizing effect of isometronidazole following its intravesical application in bladder carcinoma. A clinical phase-II study]. *Strahlenther Onkol.* 1991 Sep;167(9):530-3. German. PubMed PMID: 1925936.
- Zharkov VV, Merkle KKh, Gentshel M, Furmanchuk AV, Kurchin VP, Demidchik IuE, Moiseev PI. [The immediate results of the use of isometronidazole in the combination therapy of patients with lung cancer]. *Med Radiol (Mosk).* 1991;36(7):18-20. Russian. PubMed PMID: 1881282.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481